|
Н. Т. Ватутин, В. А. Чупина
Донецкий государственный медицинский университет им. М. Горького,
Институт неотложной и восстановительной хирургии, Донецк
В начало...
(Окончание)
Таким образом, имеющиеся сегодня данные о связи ИБС с инфекцией позволяют говорить о новой гипотезе атерогенеза. Однако результаты этих работ неоднозначны и требуют проведения дальнейших крупных многоцентровых исследований, которые смогут ответить на вопрос практической медицины: нуждаются ли больные ИБС в терапии антибиотиками?
Кардиология, N 2-2000, стр. 67-71
1. Fong I.W., Chiu B., Viira E. et al. Rabbit model for Chlamydia pneumoniae infection. J Clin Microb 1997;35:48-52.
2. Bozovich G.E., Gurfinkel E.P. Chlamydia pneumoniae: more than a bystander in acute coronary syndromes. Br J Cardiol 1998;5:84-90.
3. Danesh J., Appleby P. Persistent infection and vascular disease: A systemic rewiew (abstract). Expert Opinion on Investigational Drugs 1998;7:691-713.
4. Kuo C.C., Jackson L.A., Campbell L.A. et al. Chlamydia pneu-moniae (TWAR). Clin Microbiol Rev 1995;8:451-461.
5. Mendall M.A., Carrington D., Strachan D. et al. Chlamydia pneu-moniae: risk factors for seropositivity and association with coronary heart disease (abstract). J Infect Dis 1995;30:121-128.
6. Peeling R.W., Brunham R.C. Chlamydia as pathogens: new species and new issues. Emerging Infectious Diseases 1996;2:307-319.
7. Ramirez J., and the Chlamydia pneumoniae / Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996;125:979-982.
8. Saikku P. Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J 1993;14:62-65.
9. Gupta S., Leatham E.W., Carrington D. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithro-mycin in male survivors of myocardial infarction. Circulation 1997;96:404-407.
10. Patel P., Mendall M.A. et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995;311: 711-714.
11. Gurfinkel E., Bozovich G., Daroca A. et al. Randomized trial of roxythromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-407.
12. Lip G.Y.H., Beevers D.G. Can we treat coronary artery disease with antibiotics? Lancet 1997;350:378-379.
13. Яблучанский Н.И. Системные стереометрические модели сердца при инфаркте миокарда: Автореф. дис. ... канд. мед. наук. Краснодар 1982;16-18.
14. Anderson J.L., Carlquist J.F., Muhlestein J.B. et al. Evaluation of С-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myo-cardial infarction. J Am Coll Cardiol 1998;32:35-41.
15. Danesh J., Collins R., Appleby P. et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies (abstract). JAMA 1998;279:1477-1482.
16. Mattila K.J., Valtonen V.V., Nieminen M.S. et al. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998; 26:719-734.
17. Adam E., Melnick J.L., Pelrie B.L. et al. High levels of CMV antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987;2:291-293.
18. Benditt E.P., Barret Т., McDougall J.K. Viruses in the citology of atherosclerosis. Proc Natl Acad Sci USA 1983;80:6386-6389.
19. Gratton M.T., Moreno-Cabral C.E., Stames Y.A. et al. CMV infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;26:3561-3566.
20. Hajjar D.F. Viral pathogenesis of atherosclerosis. Am J Pathol 1991;139:1993-1211.
21. Fabricant C.G., Fabricant J., Litrenta M.M. et al. Viruses induced atherosclerosis. J Exp Med 1978;148:335-340.
22. Zhou Y.F., Martin B.L., Myron A.W. et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. New Engl J Med 1996;335:624-630.
23. Saikku P., Mattila К., Nieminen M.S. et al. Serological evidence of an association of a novel Chlamydia, TWAR, with coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-986.
24. Campbell L.A., O'Brien F.R., Cappuccio A.L. et al. Detection of Chlamydia pneumoniae (TWAR) in human coronary atherec-tomy tissue. J Infect Dis 1996;172:585-588.
25. Grayston J.T. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992;15:757-763.
26. Grayston J.T., Kuo C.C., Coulson A.S. et al. Chlamydia pneu-moniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995;92:3397-3400.
27. Grayston J.T., Thom D.H., Kuo C.C. et al. Chlamydia pneumo-niae (TWAR) and atherosclerosis (abstract). In: Chlamydial infections. Eds. J. Orfila, G. Byrne, M.A. Chernesky. Bologna: Societa Editrice Esculapio 1994.
28. Kuo C.C., Grayston J.T., Campbell L.A. et al. Chlamydia pneu-moniae (TWAR) in coronary arteries of young adults (15-35 years ). Proc Natl Acad Sci USA 1995;92:6911-6914.
29. Shor A., Kuo C.C., Patton D.L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992;82:158-161.
30. Juvonen J., Juvonen Т., Laurila A. et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms (abstract). J Vasc Surg 1997;25:499-505.
31. Kuo C.C., Shor A., Campbell L.A. et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-849.
32. Melnick S.L., Shahar E., Folsom A.R. et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med 1993; 95:499-504.
33. Laitinen К., Laurila A., Pyhala L. et al. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997;65:4832-4835.
34. Moazed T.C., Kuo C.C., Grayston J.T., Campbell L.A. An experimental model of Chlamydia pneumoniae infection. Am J Pathol 1996;148:667-676.
35. Saikku P., Leinonen M., Trnkanen L. et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116: 273-278.
36. Linnanmaki E., Leinonen M., Mattilla K. et al. Chlamydia pneu-moniae-specific circulating immune complexes in patients with chronic heart disease. Circulation 1993;87:1130-1134.
37. Thom D., Grayston J.T., Siscovick D. et al. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992;268:68-72.
38. Muhlestein J.B., Hammond E.H., Carlquist J.F. et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-1561.
39. Chui В., Viira E., Tucker В., Fong I. Chlamydia pneumoniae, cytomegalovirus and Herpes simplex virus. Circulation 1997;96: 2144-2148.
40. Blasi F., Denti F., Erba M. et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms (abstract). J Clin Microb 1996;34:2766-2769.
41. Jackson L.A., Rodriguez D.I., Lee A. et al. Isolation of Chlamy-dia pneumoniae TWAR from a carotid plaque specimen obtained by endarterectomy. J Infect Dis 1997;176:292-295.
42. Davidson M., Kuo C.C., Middaugh J.P. et al. Confirmed previous infection with Chlamydia pneumoniae ( TWAR ) and its presence in early coronary atherosclerosis. Circulation 1998;98:628-633.
43. Muhlestein J.B., Anderson J.L., Hammond E.H. et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-636.
44. Weiss S.M., Roblin P.M., Gaydos C.A. et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996;173:957-962.
45. Rasmussen S.J., Douglas F.P., Timms P. PCR detection and differentiation of Chlamydia pneumoniae, Chlamydia psittaci and Chlamy-dia trachomatis (abstract). Mol Cell Probos 1992;6:389-394.
46. Jackson L.A., Campbell L.A., Schmidt R.A. et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular ather-oma: Evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-1790.
47. Oupla S., Camm A.J. Chlamydia pneumoniae and coronary heart disease. Br Med J 1997;514:1778-1779.
48. Kaukoranta-Tolvanen S.S., Laitinen K., Saikku P., Leinonen M.
Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994;16:313-319.
49. Gaydos C.A., Smnmersgill J.T., Sahney N.N. et al. Replication of Chlamydia pneumoniae in vitro in human macrophages, en-dothelial cells, and aortic artery smooth muscle cells. Infect Immunity 1996;64:1614-1620.
50. Godzik К., O'Brien E., Wang S.K., Kuo C.C. In vitro susceptibility of human vascular wall cells to infection with Chlamy-dia pneumoniae. J Clin Microb 1995;33: 2411-2414.
51. Moazed Т.C., Kuo C.C., Grayston J.T., Campbell L.A. Evidence of systemic dissemination of Chlamydia pneumoniae via mac-rophages in the mouse. J Infect Dis 1998;177:1322-1325.
52. Kaukoranta-Tolvanen S.S., Teppo A.M., Laitinen K. et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Mi-crob Pathog 1996;21:215-221.
53. Kaukoranta-Tolvanen S.S., Ronni Т., Leinonen M. et al. Expression of adgesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog 1996;21:407-411.
54. Saikku P. Chlamydia pneumoniae and atherosclerosis-an update (abstract). Scand J Infect Dis 1997;104:Suppl:53-56.
55. Kalayoglu M.V., Byrne G.I. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis 1998;177: 725-729.
56. Laurila A., Bloigu A. Nayha S. et al. Chronic Chlamydia pneu-moniae infection is associated with serum lipid profile known to be a risk factor for atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 1997;17:2910-2913.
57. Halme S., Syrjala H., Bloigu A. et al. Lymphocyte responses to Chlamydia antigens in patients with coronary heart disease. Eur Heart J 1997;18:1095-1101.
58. Halme S., von Hertzen L., Bloigu A. et al. Chlamydia pneumoni-ae-specific cell-mediated and humoral immunity in healthy people. Scand J Immunol 1998;47: 517-520.
59. Roblin P.M., Montalban G., Hammerschlag M.R. Susceptibilities to claritromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994;38:1588-1589.
60. Sinisalo J., Mattila К., Nieminen M.S. et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production (abstract). J Antimicrob Chemother 1998;41:85-92.
Посмотреть комментарии[1]
| 
